References
- Faslodex® summary of product characteristics. London (UK): European Medicines Agency; 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000540/WC500021174.pdf. [Last accessed 6 April 2017]
- Faslodex® prescribing information. Silver Spring (MD): US Food and Drug Administration; 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021344s029lbl.pdf. [Last accessed 6 April 2017]
- Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594–600
- Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 2015;33:3781–7
- Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016;388:2997–3005
- Araki K, Ishida N, Horii R, et al. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure. Expert Opin Pharmacother 2015;16:2561–8
- Ishida N, Araki K, Sakai T, et al. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience. Breast Cancer 2016;23:617–23
- Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664–70
- Cardoso F, Costa A, Senkus E, et al. 3rd ESO–ESMO International consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 2017;28:16–33
- Kawaguchi H, Masuda N, Nakayama T, et al. Outcomes of fulvestrant therapy among Japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari). Breast Cancer Res Treat 2017;163:545–54
- National Comprehensive Cancer Network. Invasive breast cancer (Version 2.2017). Fort Washington (PA): NCCN; 2017. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [Last accessed 4 September 2017]
- Graham J, Pitz M, Gordon V, et al. Clinical predictors of benefit from fulvestrant in advanced breast cancer: a meta-analysis of randomized controlled trials. Cancer Treat Rev 2016;45:1–6
- Cope S, Ouwens MJ, Jansen JP, et al. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health 2013;16:403–17
- Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718–24
- Roché H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 2011;22:1000–10
- Barrios C, Forbes JF, Jonat W, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012;23:1378–86